Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent antileukemia cell activity

Chunling Dong, Bo Li, Zhenyu Li, Sreerama Shetty, Jian Fu

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Dasatinib (DAS), a second-generation tyrosine kinase inhibitor, is highly effective in treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. However, its clinical use is limited due to serious adverse effects. DAS can disrupt endothelial barrier integrity and increase endothelial permeability which may cause peripheral edema and pleural effusion. Albumin nanoparticles (NPs) as a drug carrier may serve as a useful tool for cell-selective drug delivery to reduce DAS-induced endothelial hyperpermeability and maintain endothelial barrier integrity. In this study, we reported that DAS-loaded NPs exhibited potent anti-leukemia efficacy as DAS alone. Importantly, albumin NPs as a drug carrier markedly reduced DAS-induced endothelial hyperpermeability by restraining the inhibition of Lyn kinase signaling pathway in endothelial cells. Therefore, albumin NPs could be a potential tool to improve anti-leukemia efficacy of DAS through its cell-selective effects.

Original languageEnglish
Pages (from-to)49699-49709
Number of pages11
JournalOncotarget
Volume7
Issue number31
DOIs
StatePublished - 2016

Keywords

  • Drug carrier
  • Endothelial barrier
  • Leukemia
  • Nanoparticles
  • Tyrosine kinase

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent antileukemia cell activity'. Together they form a unique fingerprint.

Cite this